2,2-difluoro-D-glucose

2,2-difluoro-D-glucose (2,2-diFG) is a small molecule glycolysis inhibitor being investigated for the treatment of hypoxic tumors, such as pancreatic ductal adenocarcinoma (PDAC). Developed by researchers at the UT MD Anderson Cancer Center, it is a halogenated derivative of 2-deoxy-D-glucose (2-DG). The compound acts by inhibiting the glycolytic pathway, leading to a reduction in the extracellular acidification rate (ECAR) and a decrease in cellular ATP levels. In vitro studies have demonstrated that 2,2-diFG is significantly more potent than 2-DG in inhibiting the proliferation of pancreatic cancer cells, with enhanced efficacy observed under hypoxic conditions.

Other names

2,2-difluoro-2-deoxy-D-glucose